Biopharmaceutical Industry Leader Dr. Clay Siegall

Clay Siegall is the Chief Executive Officer, Founder, Chairman and President of Seattle Genetics. He co-founded Seattle Genetics in 1998 and since has focused on antibody based cancer therapies. Dr. Siegall created the drug ADCETRIS, this was given accelerated approval by the United States Food and Drug Administration in 2011. Prior to beginning his extensive career in pharmaceutical creation he attended the University of Maryland and earned his BS in zoology and later attended George Washington University and earned his Ph.D. in Genetics.

Seattle Genetics is a biotechnology company that focuses on the creation and commercialization of antibody based cancer fighting drugs. Seattle Genetics is a leading nationally known pharmaceutical company that puts a focus on oncology. Dr. Clay Siegall was able to establish the company with capital of more than $675 million via public and private financing.

Before he founded Seattle Genetics, Dr. Siegall was employed with Bristol-Myers

Squibb Pharmaceutical Research Institute from 1991-1997. From 1988 to 1991 Dr. Siegall was employed with both the National Cancer Institute and the National Institutes of Health. In January of 2013, Mirna Therapeutics announced the appointment of Dr. Clay Siegall to their board of directors. Mirna Therapeutics is a biotechnology company that focuses on the commercialization and production of microRNA therapeutics. Dr. Siegall is a highly sought after leader in the pharmaceutical development industry. He currently has over seventy publications and has over fifteen patents.

As of January 2014 Ultragenyx proudly announced the appointment of Dr. Clay Siegall to their board of directors. Ultragenyx is a biopharmaceutical company that puts a deep focus on the treatment of ultra-rare diseases. Dr. Siegall acknowledged the advancements that Ultragenyx has made in the treatment of ultra-rare diseases and was happy to join their team to lend his expertise advice in biopharmaceutical production. In addition to Ultragenyx and Mirna Therapeutics, Dr. Clay Siegall is also on the board of governors for the Fred Hutchinson Cancer Research Center and he is on the board of directors for Alder Biopharmaceuticals.